LGR5 and neoplasm: The proliferative response increased by LGR5 suppression potentiates EGFRi sensitivity and death of adenoma cells (in keeping with the proliferative capacity of aggressive tumours rendering them more sensitive to anticancer agents (Valeriote and van Putten, 1975)).